Matthew V Holt

ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 8

Top Venues

Cancer research communications

Molecular cancer therapeutics

PLoS pathogens

Cancer research

Baylor College of Medicine (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

Baylor College of Medicine

United States

PHD :: Biochemistry

Florida Gulf Coast University

United States

BSC :: Biology

Publications

Anran Chen, Beom-Jun Kim, Aparna Mitra, Craig T Vollert, Jonathan T Lei, Diana Fandino, Meenakshi Anurag, Matthew V Holt, Xuxu Gou, Jacob B Pilcher, Matthew P Goetz, Donald W Northfelt, Susan G Hilsenbeck, C Gary Marshall, Marc L Hyer, Robert Papp, Shou-Yun Yin, Carmine De Angelis, Rachel Schiff, Suzanne A W Fuqua, Cynthia X Ma, Charles E Foulds, Matthew J Ellis
PKMYT1 is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. Molecular cancer therapeutics (2024)
Anran Chen, Beom-Jun Kim, Aparna Mitra, Craig T Vollert, Jonathan T Lei, Diana Fandino, Meenakshi Anurag, Matthew V Holt, Xuxu Gou, Jacob B Pilcher, Matthew P Goetz, Donald W Northfelt, Susan G Hilsenbeck, C Gary Marshall, Marc L Hyer, Robert Papp, Shou-Yun Yin, Carmine De Angelis, Rachel Schiff, Suzanne A W Fuqua, Cynthia X Ma, Charles E Foulds, Matthew J Ellis
PKMYT1 is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. Molecular cancer therapeutics (2024)
Beom-Jun Kim, Ze-Yi Zheng, Jonathan T Lei, Matthew V Holt, Anran Chen, Jianheng Peng, Diana Fandino, Purba Singh, Hilda Kennedy, Yongchao Dou, María Del Rosario Chica-Parrado, Emmanuel Bikorimana, Dan Ye, Yunguan Wang, Ariella B Hanker, Nada Mohamed, Susan G Hilsenbeck, Bora Lim, Jaya Ruth Asirvatham, Arun Sreekumar, Bing Zhang, George Miles, Meenakshi Anurag, Matthew J Ellis, Eric C Chang
Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted Treatment. Cancer research communications 3 (7) (2023)
Junkai Wang, Alexander B Saltzman, Eric J Jaehnig, Jonathan T Lei, Anna Malovannaya, Matthew V Holt, Meggie N Young, Mothaffar F Rimawi, Foluso O Ademuyiwa, Meenakshi Anurag, Beom-Jun Kim, Matthew J Ellis
Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding Proteins. Cancer research communications 3 (8) (2023)
Xuxu Gou, Beom-Jun Kim, Meenakshi Anurag, Jonathan T Lei, Meggie N Young, Matthew V Holt, Diana Fandino, Craig T Vollert, Purba Singh, Mohammad A Alzubi, Anna Malovannaya, Lacey Elizabeth Dobrolecki, Michael T Lewis, Shunqiang Li, Charles E Foulds, Matthew J Ellis
Kinome reprogramming is a targetable vulnerability in ESR1 fusion-driven breast cancer. Cancer research (2023)
Tao Wang, Matthew V Holt, Nicolas L Young
Early butyrate induced acetylation of histone H4 is proteoform specific and linked to methylation state. Epigenetics 13 (5) (2018)
Tao Wang, Matthew V Holt, Nicolas L Young
The histone H4 proteoform dynamics in response to SUV4-20 inhibition reveals single molecule mechanisms of inhibitor resistance. Epigenetics & chromatin 11 (1) (2018)
Yanlin Fan, Yusong R Guo, Wang Yuan, Ying Zhou, Matthew V Holt, Tao Wang, Borries Demeler, Nicolas L Young, Weiwei Zhong, Yizhi J Tao
Structure of a pentameric virion-associated fiber with a potential role in Orsay virus entry to host cells. PLoS pathogens 13 (2) (2017)

Matthew V Holt.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Matthew V Holt